Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2005-02-14
2009-06-16
Navarro, Mark (Department: 1645)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007200, C435S007600, C435S007920
Reexamination Certificate
active
07547519
ABSTRACT:
The invention relates to the discovery that a putative gene ofMycobacterium tuberculosiswith no previously identified function is responsible for the ability of the bacterium to activate thioamide drugs. SinceM. tuberculosishas a low rate of synonymous mutations, all mutations in this gene, identified as Rv3854cand now termed “EtaA,” are expected to inhibit the ability of a bacterium with the mutation to activate a thioamide or thiocarbonyl drug. Thus, detecting a bacterium with a mutation in this gene indicates that the bacterium is resistant to treatment with thioamides.
REFERENCES:
patent: 6294328 (2001-09-01), Fleischmann et al.
Cole et al,Mycobacterium tuberculosisH37Rv complete genome Accession # BX842584/c, 1998, GenEmbl, 6 pages.
Cole et al,Mycobacterium tuberculosisH37Rv complete genome Accession # C70655, 1998, GenEmbl, 3 pages.
Banerjee et al, inhA, a gene encoding a target for isoniazid and ethionamide inMycobacterium tuberculosis. 1994, Science, vol. 263, p. 227-30.
Ahern, et al., “Biochemical, Reagent Offer Scientests Good Return on Investment,”The Scientist, 1995, p. 20, vol. 9, No. 15.
Badcock, et al., Sanger Centre Wellcome Genome Campus, Direct Submission, Accession No. 283864, Jan. 14, 1997, 23 pages.
Boehringer Mannheim 1997 Biochemicals Catalog, p. 95.
DeBarber et al., “Ethionamide activation and sensitivity in multidrug-resistantMycobacterium tuberculosis,”PNAS, Aug. 2000, pp. 9677-9682, vol. 97, No. 17.
Morlock, G., et al., “ethA, inhA, and katG Loci of Ethionamide-Resistant ClinicalMycobacterium tuberculosisIsolates,”Antimicrobial Agents and Chemotherapy, Dec. 2003, pp. 3799-3805.
Phillip, et al., “An integrated map of the genome of the tubercle bacillus,Mycobacterium tuberculosisH37Rv, and comparison with Mycobacterium leprae,”PNAS, Apr. 1996, pp. 3121-3137, vol. 93.
Sreevatsan, S., et al., “Restricted structural gene polymorphism in theMycobacterium tuberculosiscomplex indicates evolutionarily recent global dissemination,”Proc. Natl. Acad. Sci.USA, Sep. 1997, pp. 9869-9874, vol. 94.
Barry, III Clifton E.
Bekker Linda-Gail
DeBarber Andrea E.
Mdluli Khisimuzi
Navarro Mark
The United States of America as represented by the Secretary of
Townsend and Townsend / and Crew LLP
LandOfFree
Methods of diagnosing multidrug resistant tuberculosis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of diagnosing multidrug resistant tuberculosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of diagnosing multidrug resistant tuberculosis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4125712